
Lilly to appeal after CHMP rejects Alzheimer's drug Kisunla
The EMA's human medicines committee has said it does not recommend approval of Eli Lilly's anti-amyloid Alzheimer's disease treatment Kisunla, saying its modest benefits don't outweigh its risks. The negative decision came even though Lilly …